GSK3 beta抗体;GSK3 beta Antibody—艾普蒂 新品

Glycogen synthase kinase 3 beta (GSK3β) is a serine/threonine kinase involved in regulating diverse cellular processes, including metabolism, cell proliferation, differentiation, and apoptosis. It plays critical roles in Wnt/β-catenin, insulin, and other signaling pathways. Dysregulation of GSK3β has been linked to diseases such as Alzheimer’s disease, diabetes, and cancer, making it a key therapeutic target. Antibodies targeting GSK3β are essential tools for studying its expression, localization, post-translational modifications (e.g., phosphorylation at Ser9 or Tyr216 residues), and interactions in biological samples. These antibodies are widely used in techniques like Western blotting, immunofluorescence, immunohistochemistry, and co-immunoprecipitation. Specific anti-GSK3β antibodies can distinguish between inactive (phospho-Ser9) and active (phospho-Tyr216) forms, aiding in functional studies. Validation often involves knockout controls, peptide blocking, or siRNA knockdown to confirm specificity. Commercially available antibodies are typically raised against conserved regions or phosphorylation sites, with monoclonal or polyclonal formats offering varying sensitivity and application suitability. Researchers rely on these reagents to investigate GSK3β’s role in disease mechanisms, drug discovery, and pathway validation, particularly in neurobiology, oncology, and metabolic research. Proper antibody selection and validation remain crucial due to potential cross-reactivity with homologous proteins like GSK3α.